2010
DOI: 10.1001/archneurol.2009.295
|View full text |Cite
|
Sign up to set email alerts
|

The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale

Abstract: To determine the estimates of minimal, moderate, and large clinically important differences (CIDs) for the Unified Parkinson's Disease Rating Scale (UPDRS). Design: Cross-sectional analysis of the CIDs for UPDRS total and motor scores was performed on patients with Parkinson disease (PD) using distribution-and anchorbased approaches based on the following 3 external standards: disability (10% on the Schwab and England Activities of Daily Living Scale), disease stage (1 stage on the Hoehn and Yahr Scale), and q… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

28
308
8
1

Year Published

2012
2012
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 440 publications
(345 citation statements)
references
References 40 publications
28
308
8
1
Order By: Relevance
“…The substantial improvements at both 12 and 24 months in MDS-UPDRS III for the AT group exceed both the minimal detectable change and the substantial minimal clinically important difference for the MDS-UPDRS III. 28 As expected, the control group did not improve at any time point and actually had a 6-point worsening in MDS-UPDRS III score, although this was not significantly different from baseline. These findings agree with those reported in a previous randomized controlled trial that assessed individuals off anti-PD medication after participation in a year-long AT class.…”
Section: Discussionsupporting
confidence: 67%
“…The substantial improvements at both 12 and 24 months in MDS-UPDRS III for the AT group exceed both the minimal detectable change and the substantial minimal clinically important difference for the MDS-UPDRS III. 28 As expected, the control group did not improve at any time point and actually had a 6-point worsening in MDS-UPDRS III score, although this was not significantly different from baseline. These findings agree with those reported in a previous randomized controlled trial that assessed individuals off anti-PD medication after participation in a year-long AT class.…”
Section: Discussionsupporting
confidence: 67%
“…4 This review also showed that resistance training reduces motor symptoms quantified by UPDRS-III scores. In this study, the mean changed score after resistance training for on-medication UPDRS-III score of 3.6 exceeds reported minimal clinically important difference (MCID) values of 2.3-2.7, 25 indicating clinically meaningful changes have occurred. In addition, Corcos et al reported a larger mean reduction of 7.2 points in off-medication UPDRS-III scores post progressive resistance training compared to the active controls.…”
Section: Discussionmentioning
confidence: 68%
“…The improvement in the motor UPDRS score (mean 5 2.8 points) appears to be meaningful because it exceeded the reported mean minimal clinically important difference of 2.5 (2.3-2.7) points. 36 The lack of significant changes on most cognitive measures could be attributable to the stability of performance on neuropsychological tests over short time spans in PD with no significant cognitive impairment. 37 However, we observed significant improvement on a measure of inhibition in a magnitude similar to that reported in an aerobic exercise study on healthy elderly.…”
Section: Increase In Vȯmentioning
confidence: 99%